Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

real-time data

- PMLiVE

GenAI for medical writers is here to stay (and it’s not as scary as we thought)

By Tom Wilson

- PMLiVE

Youth is served

Why are 18-year-olds concerned about healthcare?

- PMLiVE

Joint Clinical Assessments: bureaucratic nightmare, AI opportunity, or both?

By Manca Povsic and Andrew Dobb

Amiculum

Unrivalled Convenience – Perks of Virtual Medical Education

Explore the unrivalled convenience of virtual collaboration in medical education with our new series, "Perks of Virtual Medical Education." Learn why this flexible, efficient mode of learning is the future...

Impetus Digital

- PMLiVE

Novo Nordisk shares positive phase 3 results for Ozempic in diabetes and chronic kidney disease

Approximately 40% of people living with type 2 diabetes will develop CKD

- PMLiVE

AbbVie/Genmab’s Epkinly granted FDA accelerated approval to treat follicular lymphoma

Approximately 15,000 people develop the form of non-Hodgkin lymphoma every year in the US

- PMLiVE

FDA approves Verona’s Ohtuvayre as COPD maintenance treatment in adults

More than 390 million people worldwide are living with COPD and about half of patients experience almost daily symptoms

- PMLiVE

Takeda’s mezagitamab shows promise in immune thrombocytopenia

The rare immunoglobulin-mediated autoimmune disease affects four in every 100,000 people annually

- PMLiVE

Collaborating for change in rheumatology

Elevating the standard of care through multistakeholder consensus

- PMLiVE

An Invisible Pandemic

Join Inizio Evoke Europe and University College London’s (UCL) Faculty of Brain Sciences for an unmissable discussion on our revolutionary new white paper, Transforming Bias in Healthcare. This webinar will...

- PMLiVE

Eli Lilly partners with OpenAI to discover antimicrobials for drug-resistant pathogens

Antimicrobial resistance has been declared by WHO as one of the top ten global public health threats

- PMLiVE

AstraZeneca’s Imfinzi combination shows promise in phase 3 bladder cancer study

More than 614,000 new cases of the disease are diagnosed globally every year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links